Mark Jeffrey DeLong - 21 Jul 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Senior Vice President
Signature
/s/ David Watson, attorney-in-fact for Mark Delong
Issuer symbol
APLS
Transactions as of
21 Jul 2021
Net transactions value
-$49,480
Form type
4
Filing time
22 Jul 2021, 16:24:55 UTC
Previous filing
16 Jul 2021
Next filing
27 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $15,520 +1,000 +11% $15.52 10,490 21 Jul 2021 Direct F1
transaction APLS Common Stock Sale $65,000 -1,000 -9.5% $65.00 9,490 21 Jul 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -1,000 -2.3% $0.000000 42,000 21 Jul 2021 Common Stock 1,000 $15.52 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise from an established 10B5-1 trading plan.
F2 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.